$ADXN News

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...

Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript

Addex Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript

Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Addex Therapeutics Q1 EPS $(1.53) Down From $(1.33) YoY, Sales $10.214K Down From $78.928K YoY

Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

Addex Convenes Annual General Meeting 2026

Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript

Addex Therapeutics Q4 2025 Earnings Call Transcript

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex Therapeutics Q4 EPS $(1.50) Down From $(1.37) YoY, Sales $20.020K Up From $1.719K YoY

Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Addex Therapeutics GABAB PAM Shows Reduced Cough Frequency And Lower Ashcroft Scores In Bleomycin IPF Model

Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Addex Unit Neurosterix Eyes Q2 2026 Completion Of NTX-253 Phase 1 Study, Evaluating Safety And Pharmacokinetics In Schizophrenia Patients

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Addex Therapeutics' Novel Gamma-Aminobutyric Acid Sub-Type B Receptor (GABAB) Positive Allosteric Modulator (PAM) Drug Candidate Demonstrates Baclofen-Like Efficacy In Non-Human Primate Chronic Cough Study